Jim Cornall
Base to Base Biotech
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.
Be sure to visit the podcast's website and support the creator: www.deeptechdigest.com
Author
Jim Cornall
Category
Podcast website
Latest episode
Nov 20, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Base to Base biotech podcast 35: Gothenburg Tech Week, osteoarthritis and respiratory virus infections 14.11.2025 50:33
This week, we have conversations with Malin Kjällström, Gothenburg Tech Week Press and partnerships lead; Eliot Forster the CEO of Levicept; and Christophe Demaison, CEO of ENA Respiratory. Gothenburg Tech Week Gothenburg Tech Week is western Sweden’s largest technology event, held annually across multiple venues in the city. The 2025 edition ran from October 14–16, with a programme that includes...
Base to Base biotech podcast 34: World Immunization Day and infertility 07.11.2025 1:02:00
It’s World Immunization Day on Monday, so we had a chat with Geovax chairman, president and CEO David Dodd, and in our other conversation, we talked about infertility, with Igyxos Biotherapeutics’ chief medical officer Elke Bestel. Challenging infertility Igyxos Biotherapeutics is a French biotechnology company founded in 2017 and based in Nouzilly, France. The company focuses exclusively on infer...
Base to Base biotech podcast 33: Pain relief, fungi and psychedelics 31.10.2025 59:09
This week, we have conversations with Cosmo Feilding Mellen, CEO of Beckley Psytech; Sirli Rosenvald, CEO of Estonian company Funki, and Per von Mentzer, CEO of Swedish company PharmNovo. We spoke with Funki at Life Sciences Baltics in Vilnius, Lithuania, recently, and with von Mentzer at NLS Days in Gothenburg. Taking on pain PharmNovo AB is a biotechnology company headquartered at Medicon Villag...
Base to Base biotech podcast 32: Multi-omics data and protein degradation 24.10.2025 1:00:27
This week, we have conversations on data integration with Lithuanian company Vugene, and we talk protein degradation with Amphista Therapeutics. Multi-omics Vugene is a Lithuanian bioinformatics company focused on multi-omics data integration. Founded in 2021 by CTO Juozas Gordevičius, the company is headquartered in Kaunas. Its core offering is a software platform designed to help researchers mak...
Base to Base biotech podcast 31: Exhilarating enzymes and super socks 17.10.2025 44:59
This week, we have one interview, covering enzymes and AI with Biomatter Designs, from our visit to Life Sciences Baltics in Vilnius, Lithuania recently. And from the trip to Dublin in Ireland we talked about technology that can be useful in neurological condition diagnosis, and much more, with Danu Sports. Enzymes and AI Biomatter Designs is a Lithuania‑based biotech working at the frontier of pr...
Base to Base biotech podcast 30: Life sciences in Lithuania 09.10.2025 51:02
This week, we have three interviews done during Life Sciences Baltics, which was held in Vilnius, Lithuania recently. While we have more still to come, this week on the podcast we have conversations with Justinas Mačiulaitis, Keli Therapeutics’ founder and CEO; Arnas Karužas, CEO of Ligence; and Emilė Radytė, CEO and co-founder of Samphire Neuroscience. Ligence Ligence is a health‑tech startup usi...
Base to Base biotech podcast 29: Blood pressure and radiopharmaceuticals 03.10.2025 57:12
This week, we have two interviews again. We talk about treating high blood pressure with CEO of George Medicines, Mark Mallon, and have a conversation with Jack Hoppin, CEO of Ratio Therapeutics, and John Babich, CSO, about the field of radiotherapeutics. Blood pressure Nearly half of US adults have high blood pressure and despite all the treatments already available, three in four remain uncontro...
Base to Base biotech podcast 28: CTPS1 and ocular therapeutics 25.09.2025 49:40
This week, we have two interviews. We chat with Step Pharma CEO, Andy Parker, and also have a conversation with Re-Vana CEO, Michael O’Rourke. Ocular therapeutics Re-Vana Therapeutics and Boehringer Ingelheim recently announced a $1bn+ deal to develop long-acting ophthalmic therapies. Re-Vana Therapeutics is a privately held, US and UK based developer of ocular therapeutics and innovative ocular d...
Base to Base biotech podcast 27: Childhood Cancer Awareness Month and DNA-based technology platforms 19.09.2025 54:03
This week, we have two interviews: one to mark Childhood Cancer Awareness Month, on osteosarcoma with Paul Romness from OS Therapies; and IMUNON’s CEO, Stacy Lindborg, talking about ovarian cancer, immunotherapy, covid, and more. Interview times: 02:33 OS Therapies 23:03 IMUNON Challenging osteosarcoma OS Therapies is a clinical stage oncology company focused on the identification, development, an...
Base to Base biotech podcast 26: Stand Up To Cancer Day 12.09.2025 58:45
This week, we have three interviews to mark Stand Up To Cancer Day. We have conversations with Simon Kerry, co-founder and CEO of Curve Therapeutics; Poolbeg Pharma CEO Jeremy Skillington; and Stefano Gulla, CSO of Kling Biotherapeutics. Interview times: 03:12 Curve Therapeutics 21:32 Kling Bio 37:10 Poolbeg Pharma Microcycles to address cancer Curve Therapeutics , a private biotechnology company...
Base to Base biotech podcast 25: Molecular glue degradation 05.09.2025 39:44
This week, we have an in-depth conversation on molecular glue degradation, with Monte Rosa Therapeutics’ chief data and information officer John Castle. Interview time: 03:52 Monte Rosa Therapeutics Molecular glue degradation A recent cover article in Science showcased research that expands by more than 1,000 the number of therapeutic targets (including undruggables) accessible through a protein d...
Base to Base biotech podcast 24: Dissecting the US cuts to mRNA vaccine projects and Herantis takes on Parkinson’s disease 29.08.2025 46:25
This week, we look at Herantis Pharma's work on Parkinson's disease, with the company's CEO, Antti Vuolanto, and we have an in-depth look at the recent cuts to mRNA vaccine projects, with Jean Peccoud, GenoFAB founder and professor at Colorado State University. Interview times: 03:22 Herantis 16:28 mRNA cuts Cuts to mRNA vaccine projects The U.S. Department of Health and Human Services (HHS) recen...
Base to Base biotech podcast 23: Digitalisation in labs, and are fibroblasts the future of regenerative medicine? 22.08.2025 47:21
This week, we have a wide-ranging conversation with Anna Codina, senior director strategy and business development at SciY (part of Bruker), as we discuss artificial intelligence, and digitalisation, and the effect on labs. We also chat with Fibrobiologics’ CEO Pete O'Heeron about fibroblast spheroid technology. Interview times: 03:49 FibroBiologics 21:26 SciY SciY on the path to digitalisation Th...
Base to Base biotech podcast 22: A new treatment for dry AMD and tackling peanut allergies 15.08.2025 47:48
This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies. Interview times: 03:24 PulseSight 20:43 InnoUp Tackling dry AMD PulseSight Therapeutics SAS, an ophthalmology biotech company dev...
Base to Base biotech podcast 21: Elix drug discovery platform, and CytoAgents on CAR-T, CRS and the FDA 08.08.2025 42:48
This week, we talk about drug discovery with Shinya Yuki, co-founder and CEO of Elix Inc., and Teresa Whalen, CEO of CytoAgents, about CAR-T therapies, cytokine release syndrome, and the FDA. Interview times: 03:53 Elix 20:58 CytoAgents Elix drug discovery platform AI drug discovery company Elix, Inc . and the Life Intelligence Consortium (LINC) have announced that for the first time in the world,...
Base to Base biotech podcast 20: Terumo BCT boosts CAR-T cell manufacturing, and Orbis on macrocycles 01.08.2025 53:35
This week, our conversations are with Wenyan Leong, director of APAC commercial and global strategic partnerships for cell and gene therapies at Terumo Blood and Cell Technologies, and Morten Graugaard, CEO of Orbis Medicines. Interview times: 04:01 Terumo BCT 24:52 Orbis Medicines Terumo Blood and Cell Technologies shows integrated 3-in-1 CAR-T workflow with quantum platform Terumo Blood and Cell...
Base to Base biotech podcast 19: Nipro on dialysis and LenioBio on cell-free protein synthesis 25.07.2025 39:25
This week’s podcast is sponsored by Nipro . This week, our conversations are with Jesus Garcia, Nipro Product Manager Water Treatment, on Nipro ’s recently-launched product LiniXia, a reverse osmosis (RO) system that ensures safe and pure water for every dialysis session, and on the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke. Interview times:...
Base to Base biotech podcast 18: NETs and AI to tackle antimicrobial resistance 18.07.2025 50:39
This week, we have conversations with Eduardo Bravo, CEO of Citryll, and Dermot Tierney, COO of AMPLY Discovery. Interview times: 02:53 Citryll 21:56 AMPLY Discovery Citryll Citryll ’s recent Series B financing of €85m at the end of last year is helping to advance its first-in-class therapy targeting neutrophil extracellular traps (NETs). Discovered in 2004, NETs are web-like structures released b...
Base to Base biotech podcast 17: Silico nanoparticle gene delivery, and diagnosing urinary tract infections 11.07.2025 54:37
This week, our subjects are a silica nanoparticle gene delivery system in a conversation with Nigel Theobald, CEO of N4 Pharma, and a point-of-care diagnostics system for urinary tract infections developed by Welsh company Llusern Scientific. We spoke with the company's co-founder and CEO, Dr Emma Hayhurst. Interview times: 03:00 N4 Pharma 24:45 Llusern Scientific N4 Pharma N4 Pharma is a UK biote...
Base to Base biotech podcast 16: Domain Therapeutics, SandboxAQ and LinkGevity 04.07.2025 1:13:19
This week, we have conversations with Sean MacDonald, CEO of Domain Therapeutics, Carina Kern, CEO and founder of LinkGevity, and Nadia Harhen, general manager of AI Simulation at SandboxAQ. Interview times: 03:41 Domain Therapeutics 27:14 SandboxAQ 48:04 LinkGevity Domain Therapeutics Domain Therapeutics is delivering breakthrough GPCR-targeting therapies in immuno-oncology and inflammation. Doma...
Base to Base biotech podcast 15: Bio-convergence and cancer vaccines 27.06.2025 55:17
This week, we have conversations with Phil L'Huillier, CEO of Scancell, and Shai Melcer, head of Israel’s National Bio-Convergence Program. Interview times: 03:25 Scancell 28:04 National Bio-Convergence Program Scancell Scancell recently announced a partnership with the UK’s NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients. The company’s DNA off-the-shelf cancer va...
Base to Base biotech podcast 14: How to build reputation, and treating spastic paraplegia 47 20.06.2025 54:00
This week, we have conversations with Peter Nolan, CEO of BlackFinBio, and Kim Kraemer, CEO and founder of Waterhouse Brands. Interview times: 01:57 BlackFinBio 19:36 Waterhouse Brands BlackFinBio BlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases. Its pipeline comprises BFB-101, a clinical stage AP4B1 replacement adeno-asso...
Base to Base biotech podcast 13: Syngene commits to US market, and Nimbus Therapeutics on computational chemistry 13.06.2025 46:09
This week, we have conversations with Dr Peter Tummino, president of R&D at Nimbus, and Alex Del Priore, senior vice president, manufacturing at Syngene International Limited. Interview times: 02:00 Syngene 20:27 Nimbus Therapeutics Nimbus Therapeutics Nimbus Therapeutics is perhaps best known for two high-profile deals – Gilead’s $1.2bn acquisition of its NASH program and Takeda’s $4bn acquis...
Base to Base biotech podcast 12: CLS boosts drug discovery capabilities, and Sitryx – pioneers in immunometabolism 06.06.2025 40:31
This week, our guests are Ben Cliff, CEO of UK-based CRO, Concept Life Sciences, and Ravi Rao, chief medical officer of Sitryx. Interview times 01:12 Sitryx 19:40 CLS Concept Life Sciences Concept Life Sciences (CLS), a provider of drug discovery, development, and manufacturing services to the global pharma and biotech sector, recently announced an investment into its drug discovery capabilities....
Base to Base biotech podcast 11: Turning cancer into a chronic disease, and a different way to draw blood 30.05.2025 54:19
This week, we have a conversation with Ben Zeskind, CEO and co-founder of Immuneering, and a discussion with Tasso Inc.’s co-founder and chief technology officer, Erwin Berthier. Interview times: 01:27 Tasso 27:25 Immuneering Immuneering There is no cure for HIV, yet many people with the virus now live long, healthy lives – thanks to available medicines that prevent disease progression with minima...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.